Rosemarinic acid for COVID-19

c19early.org

COVID-19 Treatment Clinical Evidence

COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets. c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research. Only three high-profit early treatments are approved in the US. In reality, many treatments reduce risk, with 25 low-cost treatments approved across 163 countries.

Naso/oropharyngeal treatment Effective Treatment directly to the primary source of initial infection.
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.

Rosemarinic acid may be beneficial for COVID-19 according to the studies below. COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 11,000+ potential treatments. c19early.org analyzes 210+ treatments. We have not reviewed rosemarinic acid in detail.

Studies suggesting benefit with rosemarinic acid

Amrutha Pulagam, Murthi Vidya Rani, Rajitha Galla, Umakanth Naik Vankadoth, Umamaheswari Amineni, -., Molecular Docking Study of Nutraceuticals from Medicinal Plants against COVID-19 by Targeting PLPRO and RdRp, Zenodo, doi:10.5281/Zenodo.10993336

The SARS-CoV-2 infection continues triggering substantial distress to people since 2019. Many research investigationsconcerning viral pathogenesis regarding the manner in which the virus infects and multiplies within the host have led toconverging conclusions. Numerous studies have additionally demonstrated a strong link between ageing, mildinflammation, metabolic disorders and SARS-CoV-2 illness. According to a modest collection of knowledge, nutraceuticals arecapable of avoiding viral invasion and can reduce inflammation. Consequently, in this current work, we report a moleculardocking analysis for nutraceuticals from diverse plants against SARS-CoV-2 cysteine proteases PLpro (PDB ID: 7CJM) andRNA dependent RNA polymerase (RdRp, PDB ID: 6M71) which play major role in viral replication. The molecular dockingstudies showed that chicoric acid (7CJM : -8.617 Kcal/Mol, 6M71: -6.475) and rosemarinic acid (7CJM : -7.925 Kcal/Mol,6M71 : -8.323 Kcal/Mol) exhibited good docking scores with the selected targets, which were better when compared to that ofreference antiviral drugs Remdesivir and Favipiravir. The majority of the nutraceuticals assessed by Qikprop displayedbeneficial pharmacological characteristics for human administration.

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

COVID-19 pandemic caused by the novel SARS-CoV-2 has impacted human livelihood globally. Strenuous efforts have been employed for its control and prevention; however, with recent reports on mutated strains with much higher infectivity, transmissibility, and ability to evade immunity developed from previous SARS-CoV-2 infections, prevention alternatives must be prepared beforehand in case. We have perused over 128 recent works (found on Google Scholar, PubMed, and ScienceDirect as of February 2023) on medicinal plants and their compounds for anti-SARS-CoV-2 activity and eventually reviewed 102 of them. The clinical application and the curative effect were reported high in China and in India. Accordingly, this review highlights the unprecedented opportunities offered by medicinal plants and their compounds, candidates as the therapeutic agent, against COVID-19 by acting as viral protein inhibitors and immunomodulator in (32 clinical trials and hundreds of in silico experiments) conjecture with modern science. Moreover, the associated foreseeable challenges for their viral outbreak management were discussed in comparison to synthetic drugs.